Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: A patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials
28 August 2022 (09:00 - 09:10)
Organised by:
About the speaker
Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)
2 More presentations in this session
Doctor T. Osadnik (Zabrze, PL)
Doctor S. Parveen (Copenhagen, DK)
Access the full session
The Event
ESC Congress 2022
28 August 2022
09:00 CET
You may be interested in
Congress Presentation
